ClinicalTrials.gg
Enrolling by invitationNCT07367841FIND HFUpdated Oct 2, 2026

FIND HF Risk-guided Screening for Heart Failure - Pilot Study

An observational study in Heart Failure, sponsored by University of Leeds. Enrolling by invitation at 1 site in United Kingdom. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2026-10-02.

Sponsored by University of Leeds · Observational

How we know

Updated Oct 2, 2026Now Enrolling by invitationFirst site in United Kingdom+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
475
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 15 studies in Heart Failure by University of Leeds — 4 open to participants now, 5 under way, none of them phase 3. Heart Failure · University of Leeds.

Started
2026
the only one that year
Observational
5 of 15
4 open now
Registered
14th of 15
by date

Among the 15 studies in Heart Failure by University of Leeds, this one is the only one that started in 2026, is one of 5 observational ones, and was the 14th registered.

Heart Failure

6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.

Browse Heart Failure studies →

Open to participants now

4 of the 15 studies in Heart Failure by University of Leeds are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.

This study: 40 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Heart Failure by University of Leeds, or all of them as a file.
02

Study summary

The goal of this clinical trial is to learn if the FIND HF algorithm detection rates of heart failure during testing are higher amongst participants identified as high FIND-HF risk compared to those identified as low risk in a population identified as at risk of undiagnosed heart failure. The main questions it aims to answer are:

  • Are people who are identified as high risk by the FIND-HF tool more likely to be diagnosed with heart problems during testing than those identified as low risk?
  • Are people identified as high risk by the FIND-HF tool more likely to show signs of heart problems during testing than those identified as low risk?? Researchers will compare patients in the high risk and low risk groups to see if more patients are detected with asymptomatic heart failure in the high risk group compared to the low risk group.

Participants will attend one visit at a local clinic where they will undergo an NT proBNP blood test which indicates heart failure and an echocardiogram to evaluate the heart's chambers, valves and overall function to help diagnose various heart conditions.

Read the detailed description

Background Heart failure (HF) affects around 1-2% of adults globally and is a leading cause of unplanned hospital admissions, especially among older people. In the UK alone, over one million people have HF, with about 200,000 new cases each year. This increase is mainly due to an aging population and better survival rates following heart attacks.

From the perspective of treatment, there are three main categories of HF:

  • HF with reduced ejection fraction (HFrEF)
  • HF with mid-range ejection fraction (HFmrEF)
  • HF with preserved ejection fraction (HFpEF) For HFrEF, four pillar therapy (diuretics, beta-blockers, angiotensin-converting enzyme inhibitors, lanoxin) is established as the gold standard for pharmacotherapeutic management, helping to reduce the risk of death and hospital admissions. For HFpEF and HFmrEF, medications like empagliflozin, dapagliflozin, and finerenone have shown promising results in reducing risks. New drugs like Semaglutide and Tirzepatide are also beneficial for HFpEF patients with obesity. There are now more treatment options for HF than ever before.

In the UK, nurse-led teams in the community are capable of initiating and adjusting HF treatments. However, diagnosing HF early, before severe symptoms appear, remains challenging. Current guidelines recommend specific tests for diagnosis, but many (8 out of 10) diagnoses are still made in hospitals, often late.

The NHS aims to improve early diagnosis in primary care to reduce hospital admissions and improve patients' quality of life.

Funded by the British Heart Foundation (BHF) the investigators have developed an AI algorithm, FIND-HF, to identify people at risk of undiagnosed HF using data from routinely collected electronic health records.

Aims of the project The research project aims to determine the effectiveness of the FIND-HF AI algorithm in identifying HF at different risk levels and to understand the potential benefits of early detection and treatment.

The investigators will quantify the burden of symptoms, natriuretic peptide levels, and diagnostic yield of asymptomatic left ventricular systolic dysfunction, HFrEF, HFmrEF, and HFpEF at different FIND-HF AI risk scores. Using this information, the investigators will establish the risk score threshold that would be used for a future randomised clinical trial (RCT) of early detection of HF.

In addition, amongst patients newly diagnosed with HF during the study, the investigators seek to quantify the pharmacological treatment opportunities to inform the potential effect size, and thus sample size, of a future RCT of early detection and treatment of HF to reduce heart failure hospitalisation and cardiovascular death.

Identification of participants and recruitment Participants will be identified through by having their HF risk estimated their primary care electronic health records.

Individuals will be divided into two categories based on the predicted HF risk with recruitment 1:2 guided by risk strata, with 151 participants in the top 10 percentiles of risk, and 302 participants from the bottom 90 percentiles. This approach aims to enrich the cohort with higher risk patients while also including lower risk patients to determine whether there is an increase in the yield of new HF diagnosis from across the range of FIND-HF AI risk estimates.

Study invitations will be sent to eligible participants in each risk category in batches until the target sample size is reached. The invitation process will consist of a text message followed by an information pack in the post including a participant information sheet, consent form, contact information form and freepost return envelope. Participants will return the consent form and contact information to the research team who will then contact them to make an appointment for the study visit. The study visit will take place at the participant's GP surgery or a community-based health hub.

All participants will be required to provide written informed consent. Study visit

Consenting participants will attend one study visit. During the visit, a British Society of Echocardiography (BSE)-accredited clinical member of the research team will carry out the following tests/investigations:

  • Medical history and symptom assessment (breathlessness, orthopnea, paroxysmal nocturnal dyspnea, exercise intolerance, fatigue, ankle swelling)
  • Height, Weight, HR and BP
  • Natriuretic peptide testing: Participants will undergo point of care (POC) natriuretic peptide testing
  • Echocardiography: Participants will receive an AI-enabled hand-held echocardiogram using the Kosmos device and US2.ai automated measurements.

New cases of HF will be reported to the participant and their GP. Their GP will have responsibility to refer the participant as per local protocol.

Follow up Participants will be followed up remotely through their primary care EHRs at 6 months, and 1-, 5- and 10-years from their study visit by a member of the research team. Follow-up will include assessment of HF therapy and HF events. Consent will be sought for linkage to secondary care records, death certificate data and national registries.

Expected value of results The NHS Major Conditions Strategy stresses the need for evolving care models to better serve the public, with a focus on early diagnosis of cardiovascular disease using AI and digital technology. This proof-of-concept study will inform the design of a trial to test AI risk stratification and community-based pathways for early diagnosis and treatment of heart failure (HF), aiming to reduce HF events and cardiovascular death. If successful, the AI model (FIND-HF) could be implemented across UK primary care for a community-based early HF diagnostic pathway in the NHS.

03

Conditions studied

  • Heart Failure

Browse trials for

Keywords

  • Artificial Intelligence
  • Data Science
  • Health Inequalities
  • Heart Failure
04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients identified at risk of developing Heart Failure by the FIND HF algorithm and are aged 40 and over, living in the Yorkshire area.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Registered with a doctor practice that uses electronic health system to record patient medical notes Age at enrolment greater or equal to 40 Identified as at risk of developing Heart Failure

Exclusion criteria

Exclusion Criteria:

Registered with a doctor practice that is participating in research studies relating to heart failure screening

  • Known diagnosis of HF
  • On the palliative care register
  • Unable to give written for participation in the study
  • Unable to adhere to the study requirements
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
475 participants (estimated)
Patient registry
No

Groups and cohorts

  • Patients at risk of developing Heart Failure

    Patients will attend one visit with a Cardiology specialist Clinical research fellow who will carry out tests to detect Heart Failure

    Diagnostic Test: FIND HF algorithm

Interventions

  • Diagnostic testFIND HF algorithm

    Algorithm developed by the research team to identify patients at risk of heart failure that is currently undetected.

06

What researchers measure

Primary outcomes

  1. To determine whether detection rates of a composite of asymptomatic LVSD, HFrEF, HFmREF, or HFpEF during diagnostics are higher amongst participants identified as high FIND-HF risk compared to those identified as low risk

    Odds ratio of asymptomatic LVSD, HFrEF, HFmREF, or HFpEF detection rates from intervention in people identified as high HF risk compared with people identified as low HF risk

    Time frame: Through study completion, an average of 12 months from date of enrolment

Secondary outcomes

  1. To determine if components of composite outcome during diagnostics are higher amongst participants identified as high FIND-HF risk compared to those identified as low risk

    Odds ratio for each component of the composite in in people identified as high HF risk compared with people identified as low HF risk

    Time frame: Through study completion, an average of 12 months from date of enrolment

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No — Planning to commercialise algorithm

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2026 (actual). Primary completion is estimated for Jul 2027, 10 months after the start.

Of 799 non-industry observational studies under Heart Failure, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 100. This study's planned 10 months is below that.

Counting every sponsor, half of 982 studies reached it within 41 months; a quarter within 23 and three quarters within 89.

Start moved once since we started tracking on Sep 25, 2026: Feb 2026 → Sep 2026, on Oct 2, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Sep 30, 2025
First posted
Jan 26, 2026
StartActual
Sep 24, 2026was Feb 2026
Primary completionEst.
Jul 2027
CompletionEst.
Oct 2028
Last update
Oct 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Enrolling by invitation
changed Oct 2, 2026
Sites
1 site added — first site in United Kingdom
Show site
  • University of Leeds · Leeds, United Kingdom
Oct 2, 2026
Start date
Feb 2026→Sep 24, 2026 (actual)
Oct 2, 2026
Contact
No study contact listed any more: removed r•••@nhs.net · •••7000; removed m•••@leeds.ac.uk · •••7000
Oct 2, 2026
Show all 1 update
  1. Oct 2, 2026
    Not yet recruiting→Enrolling by invitation
    1 site added — first site in United Kingdom
    Show site
    • University of Leeds · Leeds, United Kingdom
    Start date Feb 2026→Sep 24, 2026 (now actual)
    Contact No study contact listed any more: removed r•••@nhs.net · •••7000; removed m•••@leeds.ac.uk · •••7000
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07367841
Responsible party
Prof Christopher Gale (Professor of Cardiovascular Medicine, University of Leeds) — Principal investigator
First posted
Jan 26, 2026
Start date
Sep 24, 2026
Primary completion
Jul 2027 (estimated)
Completion
Oct 2028 (estimated)
Last update
Oct 2, 2026

Study contacts

Chris P. Gale, Yes
study chair · University of Leeds

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion